{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:08:50Z","timestamp":1740107330323,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with CLN2 suffer from epileptic seizures, rapid psychomotor decline and vision loss in early childhood. The aim of the study was to provide longitudinal ophthalmic data of patients with confirmed genetic mutation and non-classical disease course, marked by later onset, protracted progression and prolonged life span.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective, observational study to assess visual acuity, retinal features (Weil Cornell Ophthalmic Score), central retinal thickness (CRT) measured by optical coherence tomography and general disease progression (Hamburg CLN2 motor language score) in non-classical CLN2 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All patients received intracerebroventricular enzyme replacement therapy with cerliponase alfa. Mean age at last follow-up was 12.4\u00a0years; mean follow-up time 2.6\u00a0years. All cases demonstrated a stable Hamburg motor language CLN2 Score and Weill Cornell LINCL Ophthalmic Severity Score. Visual function remained stable in 4\/6 patients, 2\/6 patients showed a decrease, 4\/6 cases had a stable CRT and 2\/6 showed a reduction of CRT. One patient showed a massive macular thinning and low vision. A correlation with a specific mutation or age could not be verified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The presented longitudinal study characterizes the variable ocular involvement in non-classical CLN2 disease and contributes to the natural history description. The functional and morphologic data outline the necessity of regular ophthalmic examination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary statement\n<\/jats:title>\n                <jats:p>Ocular phenotyping and description of retinal degeneration in non-classical CLN2 disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-022-05662-1","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T06:03:41Z","timestamp":1654149821000},"page":"3693-3700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Visual perception and macular integrity in non-classical CLN2 disease"],"prefix":"10.1007","volume":"260","author":[{"given":"Yevgeniya","family":"Atiskova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Wibbeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Stephan","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schwering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-9714","authenticated-orcid":false,"given":"Simon","family":"Dulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"5662_CR1","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","volume":"1852","author":"SE Mole","year":"2015","unstructured":"Mole SE, Cotman SL (2015) Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta 1852:2237\u20132241. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.011","journal-title":"Biochim Biophys Acta"},{"key":"5662_CR2","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/B978-0-444-59565-2.00038-1","volume":"113","author":"B Chabrol","year":"2013","unstructured":"Chabrol B, Caillaud C, Minassian B (2013) Neuronal ceroid lipofuscinoses. Handb Clin Neurol 113:1701\u20131706. https:\/\/doi.org\/10.1016\/B978-0-444-59565-2.00038-1","journal-title":"Handb Clin Neurol"},{"key":"5662_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bbadis.2006.06.010","volume":"1762","author":"M Haltia","year":"2006","unstructured":"Haltia M (2006) The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta 1762:850\u2013856. https:\/\/doi.org\/10.1016\/j.bbadis.2006.06.010","journal-title":"Biochim Biophys Acta"},{"key":"5662_CR4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2012.08.012","volume":"1832","author":"M Haltia","year":"2013","unstructured":"Haltia M, Goebel HH (2013) The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta 1832:1795\u20131800. https:\/\/doi.org\/10.1016\/j.bbadis.2012.08.012","journal-title":"Biochim Biophys Acta"},{"key":"5662_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams RE, Mole SE (2012) New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 79:183\u2013191. https:\/\/doi.org\/10.1212\/WNL.0b013e31825f0547","journal-title":"Neurology"},{"key":"5662_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los RE, Denecke J, Drago K, Fairhurst C, Frazier M, Guelbert N, Kiss S, Kofler A, Lawson JA, Lehwald L, Leung MA, Mikhaylova S, Mink JW, Nickel M, Shediac R, Sims K, Specchio N, Topcu M, von Lobbecke I, West A, Zernikow B, Schulz A (2017) Management strategies for CLN2 disease. Pediatr Neurol 69:102\u2013112. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.01.034","journal-title":"Pediatr Neurol"},{"key":"5662_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, Pagovich OE, Kosofsky B, Yohay K, Downs M, Slasor P, Ajayi T, Crystal RG, Kohlschutter A, Sondhi D, Schulz A (2018) Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2:582\u2013590. https:\/\/doi.org\/10.1016\/S2352-4642(18)30179-2","journal-title":"Lancet Child Adolesc Health"},{"key":"5662_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, Kohlschutter A (2002) Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 112:347\u2013354. https:\/\/doi.org\/10.1002\/ajmg.10660","journal-title":"Am J Med Genet"},{"key":"5662_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.01.011","author":"KD Kovacs","year":"2020","unstructured":"Kovacs KD, Patel S, Orlin A, Kim K, Van Everen S, Conner T, Sondhi D, Kaminsky SM, D\u2019Amico DJ, Crystal RG, Kiss S (2020) Symmetric age association of retinal degeneration in patients with CLN2-associated batten disease. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2020.01.011","journal-title":"Ophthalmol Retina"},{"issue":"Pt 3b","key":"5662_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/eye.1998.148","volume":"12","author":"RG Weleber","year":"1998","unstructured":"Weleber RG (1998) The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Eye (Lond) 12(Pt 3b):580\u2013590. https:\/\/doi.org\/10.1038\/eye.1998.148","journal-title":"Eye (Lond)"},{"key":"5662_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2007.08.124","volume":"93","author":"C Bessa","year":"2008","unstructured":"Bessa C, Teixeira CA, Dias A, Alves M, Rocha S, Lacerda L, Loureiro L, Guimaraes A, Ribeiro MG (2008) CLN2\/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype. Mol Genet Metab 93:66\u201373. https:\/\/doi.org\/10.1016\/j.ymgme.2007.08.124","journal-title":"Mol Genet Metab"},{"key":"5662_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jns.2015.05.021","volume":"356","author":"R Di Giacopo","year":"2015","unstructured":"Di Giacopo R, Cianetti L, Caputo V, La Torraca I, Piemonte F, Ciolfi A, Petrucci S, Carta C, Mariotti P, Leuzzi V, Valente EM, D\u2019Amico A, Bentivoglio A, Bertini E, Tartaglia M, Zampino G (2015) Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: clinical, molecular and biochemical characterization in three sibs. J Neurol Sci 356:65\u201371. https:\/\/doi.org\/10.1016\/j.jns.2015.05.021","journal-title":"J Neurol Sci"},{"key":"5662_CR13","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/humu.23860","volume":"40","author":"E Gardner","year":"2019","unstructured":"Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE (2019) Mutation update: review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat 40:1924\u20131938. https:\/\/doi.org\/10.1002\/humu.23860","journal-title":"Hum Mutat"},{"key":"5662_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gene.2012.12.058","volume":"516","author":"R Kohan","year":"2013","unstructured":"Kohan R, Carabelos MN, Xin W, Sims K, Guelbert N, Cismondi IA, Pons P, Alonso GI, Troncoso M, Witting S, Pearce DA, Dodelson de Kremer R, Oller-Ramirez AM, Noher de Halac I (2013) Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. Gene 516:114\u2013121. https:\/\/doi.org\/10.1016\/j.gene.2012.12.058","journal-title":"Gene"},{"key":"5662_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/humu.21624","volume":"33","author":"M Kousi","year":"2012","unstructured":"Kousi M, Lehesjoki AE, Mole SE (2012) Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 33:42\u201363. https:\/\/doi.org\/10.1002\/humu.21624","journal-title":"Hum Mutat"},{"key":"5662_CR16","doi-asserted-by":"publisher","unstructured":"Wibbeler E, Wang R, Reyes EL, Specchio N, Gissen P, Guelbert N, Nickel M, Schwering C, Lehwald L, Trivisano M, Lee L, Amato G, Cohen-Pfeffer J, Shediac R, Leal-Pardinas F, Schulz A (2020) Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series. J Child Neurol 883073820977997.https:\/\/doi.org\/10.1177\/0883073820977997","DOI":"10.1177\/0883073820977997"},{"key":"5662_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.15250","author":"CM Louren\u00e7o","year":"2020","unstructured":"Louren\u00e7o CM, Pessoa A, Mendes CC, Rivera-Nieto C, Vergara D, Troncoso M, Gardner E, Mallorens F, Tavera L, Lizcano LA, Atanacio N, Guelbert N, Specola N, Mancilla N, de Souza CFM, Mole SE (2020) Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: insights from the largest cohort in the world. J Paediatr Child Health. https:\/\/doi.org\/10.1111\/jpc.15250","journal-title":"J Paediatr Child Health"},{"key":"5662_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00401-008-0349-3","volume":"116","author":"M Elleder","year":"2008","unstructured":"Elleder M, Dvorakova L, Stolnaja L, Vlaskova H, Hulkova H, Druga R, Poupetova H, Kostalova E, Mikulastik J (2008) Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency. Acta Neuropathol 116:119\u2013124. https:\/\/doi.org\/10.1007\/s00401-008-0349-3","journal-title":"Acta Neuropathol"},{"key":"5662_CR19","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke JP, Cahan H, Slasor P, Jacoby D, Kohlschutter A, Group CLNS (2018) Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 378:1898\u20131907. https:\/\/doi.org\/10.1056\/NEJMoa1712649","journal-title":"N Engl J Med"},{"key":"5662_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073128","volume":"8","author":"A Orlin","year":"2013","unstructured":"Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, Hackett NR, Yohay K, Kosofsky B, Souweidane MM, Kaplitt MG, D\u2019Amico DJ, Crystal RG, Kiss S (2013) Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS ONE 8:e73128. https:\/\/doi.org\/10.1371\/journal.pone.0073128","journal-title":"PLoS ONE"},{"key":"5662_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41433-020-01177-3","volume":"35","author":"A Banc","year":"2021","unstructured":"Banc A, Ungureanu MI (2021) Normative data for optical coherence tomography in children: a systematic review. Eye (Lond) 35:714\u2013738. https:\/\/doi.org\/10.1038\/s41433-020-01177-3","journal-title":"Eye (Lond)"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05662-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T18:05:44Z","timestamp":1666202744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05662-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5662"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05662-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"type":"print","value":"0721-832X"},{"type":"electronic","value":"1435-702X"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University Medical Center Hamburg-Eppendorf and the Ethikkomission Hamburg, Germany and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}